Semaglutide-induced satiation, nausea, and food reward suppression are mediated by GLP-1 receptors in the area postrema

Abstract

The GLP-1-based obesity drug semaglutide lowers bodyweight primarily by increasing satiation and satiety, whilst also reducing food reward and commonly causing nausea. The brainstem dorsal vagal complex (DVC) has been identified as a key site of action for these phenotypic components of semaglutides anorectic effect.

The paper